Urinary tract infections resistant to other antibiotics.
Adults: 900 mg QID x 1/52, reduced in chronic infections to 600mg QID. By mouth:Child 3 months-12 years 12.5 mg/kg QID x 1/52, reduced to 7.5 mg/kg QID in prolonged therapy or 15 mg/kg BD for prophylaxis. Child 12-18 years 900 mg QID x 1/52, reduced in chronic infections to 600 mg QID.
Mode of action
Brands containing this Ingredient
Nalidixic acid, Allied.
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
Interferes with bacterial DNA synthesis by inhibiting topoisomerase II [DNA gyrase] and topoisomerase IV.
Should be given with care to patients with hepatic or moderate renal impairment, severe cerebral arteriosclerosis, or G6PD deficiency. Blood counts and renal and hepatic function should be monitored if treatment continues for more than 2 weeks. It should be avoided in infants less than 3 months old. Tendon damage may occur rarely and treatment should be stopped if patients have tendon pain, inflammation, or rupture.
patients with a history of convulsive disorders and in those with severe renal impairment.